Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct.
Dreier T, Baeuerle PA, Fichtner I, Grün M, Schlereth B, Lorenczewski G, Kufer P, Lutterbüse R, Riethmüller G, Gjorstrup P, Bargou RC. Dreier T, et al. Among authors: bargou rc. J Immunol. 2003 Apr 15;170(8):4397-402. doi: 10.4049/jimmunol.170.8.4397. J Immunol. 2003. PMID: 12682277
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N, Brandl C, Lippold S, Cobb K, Brasky K, Leo E, Bargou R, Murthy K, Baeuerle PA. Schlereth B, et al. Among authors: bargou r. Cancer Immunol Immunother. 2006 May;55(5):503-14. doi: 10.1007/s00262-005-0001-1. Epub 2005 Jul 20. Cancer Immunol Immunother. 2006. PMID: 16032400 Free PMC article.
The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct.
Brandl C, Haas C, d'Argouges S, Fisch T, Kufer P, Brischwein K, Prang N, Bargou R, Suzich J, Baeuerle PA, Hofmeister R. Brandl C, et al. Among authors: bargou r. Cancer Immunol Immunother. 2007 Oct;56(10):1551-63. doi: 10.1007/s00262-007-0298-z. Epub 2007 Feb 20. Cancer Immunol Immunother. 2007. PMID: 17310380 Free PMC article.
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.
Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P. Bargou R, et al. Science. 2008 Aug 15;321(5891):974-7. doi: 10.1126/science.1158545. Science. 2008. PMID: 18703743 Clinical Trial.
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells.
d'Argouges S, Wissing S, Brandl C, Prang N, Lutterbuese R, Kozhich A, Suzich J, Locher M, Kiener P, Kufer P, Hofmeister R, Baeuerle PA, Bargou RC. d'Argouges S, et al. Among authors: bargou rc. Leuk Res. 2009 Mar;33(3):465-73. doi: 10.1016/j.leukres.2008.08.025. Epub 2008 Oct 2. Leuk Res. 2009. PMID: 18835037
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, Köhne-Volland R, Brüggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethmüller G, Hoelzer D, Zugmaier G, Bargou RC. Topp MS, et al. Among authors: bargou rc. J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16. J Clin Oncol. 2011. PMID: 21576633 Clinical Trial.
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gökbuget N, Neumann S, Goebeler M, Viardot A, Stelljes M, Brüggemann M, Hoelzer D, Degenhard E, Nagorsen D, Baeuerle PA, Wolf A, Kufer P. Klinger M, et al. Blood. 2012 Jun 28;119(26):6226-33. doi: 10.1182/blood-2012-01-400515. Epub 2012 May 16. Blood. 2012. PMID: 22592608 Free article. Clinical Trial.
Blinatumomab: a historical perspective.
Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Nagorsen D, et al. Among authors: bargou r. Pharmacol Ther. 2012 Dec;136(3):334-42. doi: 10.1016/j.pharmthera.2012.07.013. Epub 2012 Aug 24. Pharmacol Ther. 2012. PMID: 22940266 Review.
157 results